Unknown

Dataset Information

0

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017.


ABSTRACT: Eravacycline is a novel, fully synthetic fluorocycline antibiotic developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. Here, we evaluated the in vitro activities of eravacycline and comparator antimicrobial agents against a global collection of frequently encountered clinical isolates of Gram-negative bacilli. The CLSI broth microdilution method was used to determine MIC data for isolates of Enterobacterales (n?=?13,983), Acinetobacter baumannii (n?=?2,097), Pseudomonas aeruginosa (n?=?1,647), and Stenotrophomonas maltophilia (n?=?1,210) isolated primarily from respiratory, intra-abdominal, and urinary specimens by clinical laboratories in 36 countries from 2013 to 2017. Susceptibilities were interpreted using both CLSI and EUCAST breakpoints. Multidrug-resistant (MDR) isolates were defined by resistance to agents from ?3 different antimicrobial classes. The MIC90s ranged from 0.25 to 1??g/ml for Enterobacteriaceae and were 1??g/ml for A. baumannii and 2??g/ml for S. maltophilia, Proteus mirabilis, and Serratia marcescens Eravacycline's potency was up to 4-fold greater than that of tigecycline against genera/species of Enterobacterales, A. baumannii, and S. maltophilia The MIC90s for five of six individual genera/species of Enterobacterales and A. baumannii were within 2-fold of the MIC90s for their respective subsets of MDR isolates, while the MDR subpopulation of Klebsiella spp. demonstrated 4-fold higher MIC90s. Eravacycline demonstrated potent in vitro activity against the majority of clinical isolates of Gram-negative bacilli, including MDR isolates, collected over a 5-year period. This study further underscores the potential benefit of eravacycline in the treatment of infections caused by MDR Gram-negative pathogens.

SUBMITTER: Morrissey I 

PROVIDER: S-EPMC7038303 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>In Vitro</i> Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017.

Morrissey Ian I   Olesky Melanie M   Hawser Stephen S   Lob Sibylle H SH   Karlowsky James A JA   Corey G Ralph GR   Bassetti Matteo M   Fyfe Corey C  

Antimicrobial agents and chemotherapy 20200221 3


Eravacycline is a novel, fully synthetic fluorocycline antibiotic developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. Here, we evaluated the <i>in vitro</i> activities of eravacycline and comparator antimicrobial agents against a global collection of frequently encountered clinical isolates of Gram-negative bacilli. The CLSI broth microdilution method was used to determine MIC data for isolates of <i>Enterobacterales</i> (<i>n</i> = 1  ...[more]

Similar Datasets

| PRJNA391501 | ENA
| PRJNA353060 | ENA
| S-EPMC6105828 | biostudies-literature
| S-EPMC5666006 | biostudies-literature